Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Sunshine Biopharma (SBFM) over the last 11 years, with Q3 2025 value amounting to $96163.0.

  • Sunshine Biopharma's Depreciation & Amortization (CF) rose 4878.08% to $96163.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $298888.0, marking a year-over-year increase of 4908.54%. This contributed to the annual value of $223527.0 for FY2024, which is 4987.03% up from last year.
  • Per Sunshine Biopharma's latest filing, its Depreciation & Amortization (CF) stood at $96163.0 for Q3 2025, which was up 4878.08% from $72533.0 recorded in Q2 2025.
  • In the past 5 years, Sunshine Biopharma's Depreciation & Amortization (CF) registered a high of $96163.0 during Q3 2025, and its lowest value of $789.0 during Q3 2022.
  • In the last 5 years, Sunshine Biopharma's Depreciation & Amortization (CF) had a median value of $34884.0 in 2023 and averaged $33898.3.
  • Per our database at Business Quant, Sunshine Biopharma's Depreciation & Amortization (CF) plummeted by 7521.21% in 2022 and then soared by 461482.89% in 2023.
  • Over the past 5 years, Sunshine Biopharma's Depreciation & Amortization (CF) (Quarter) stood at $3184.0 in 2021, then skyrocketed by 496.01% to $18977.0 in 2022, then surged by 123.18% to $42353.0 in 2023, then skyrocketed by 54.41% to $65399.0 in 2024, then soared by 47.04% to $96163.0 in 2025.
  • Its last three reported values are $96163.0 in Q3 2025, $72533.0 for Q2 2025, and $64793.0 during Q1 2025.